Silo Pharma, Inc. $SILO

What the company doesAI summary of filing

Silo Pharma, Inc. is a developmental-stage biopharmaceutical and cryptocurrency company focused on developing novel therapeutics for underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system diseases using conventional drugs and psychedelic formulations. The company's lead program, SPC-15, is an intranasal drug for PTSD and stress-induced anxiety disorders currently in preclinical and GLP-compliant studies with an IND submission targeted for 2026. The company generates minimal revenue and is pre-clinical to early clinical stage; it has entered into license agreements with universities including Columbia University and the University of Maryland, Baltimore to develop and commercialize its product candidates. In August 2025, the company adopted a cryptocurrency treasury strategy focused on acquiring digital assets including Bitcoin, Ethereum, and Solana. [10-K 2026-03-27]

Segments: SPC-15 (intranasal PTSD and anxiety treatment), SP-26 (ketamine implant for fibromyalgia and chronic pain), SPC-14 (Alzheimer's disease treatment), SPU-16 (CNS-homing peptide for multiple sclerosis)